PROGNOSTIC SIGNIFICANCE OF REARRANGEMENTS OF EML4-ALK IN PATIENTS WITH STAGE TI-II ADENOCARCINOMA IN THE RELATIONSHIP WITH SOME CLINICAL AND MORPHOLOGICAL PARAMETERS


Cite item

Full Text

Abstract

The purpose of the study: determination of ALK gene status (mutation) in patients with stage TI-II adenocarcinoma in the relationship with survival, stage, size, metastases in bronchopulmonary lymph nodes and the amplification of Her2/Neu. Materials. 98 stage I-II adenocarcinoma patients. Cases with a mutation in ALK account for 20 (4.8% without randomization). There was used the immunohistochemical method and in situ hybridization. Results. The survival rate of adenocarcinoma patients with metastases in the lymph nodes was lower than in cases without metastases: 8.3 ± 7.8% and 40.9 ± 13% respectively. None of patients with a mutation ALK lived up to 9 years in contrast to the cases without mutations (37.4 ± 12.6%). In the presence of amplification of the Her2 gene survival rate in adenocarcinoma patients was lower if compared to cases without amplification (p = 0.02). Correlation between ALK mutation and amplification of Her2 with increased N is not revealed. Thus, an independent criterion of the prognosis for cases with of stage I-II lung adenocarcinoma is the N index (χ2 = 9.6, p = 0.001). The rate of mutation of ALK was lower, but had the second largest impact on the prognosis (χ2 = 7.7, p = 0.005).

About the authors

Ashot M. Avdalyan

Altai Branch of the N.N. Blokhin Russian Cancer Research Center

Email: ashot_avdalyan@mail.ru
MD, PhD, DSc, Senior Researcher of the Laboratory of Investigations of Molecular Genetic Characteristics of Tumors of the Altai Branch of the N.N. Blokhin Russian Cancer Research Center; Barnaul, 656049, Russian Federation Barnaul, 656049, Russian Federation

A. U Panasyan

Altai Branch of the N.N. Blokhin Russian Cancer Research Center

Barnaul, 656049, Russian Federation

A. A Ivanov

Altai Branch of the N.N. Blokhin Russian Cancer Research Center

Barnaul, 656049, Russian Federation

O. V Samuilenkova

Altai Krai Oncology Centre

Barnaul, 656043, Russian Federation

S. Y Bakharev

Altai Krai Oncology Centre

Barnaul, 656043, Russian Federation

A. S Bliznyuk

Altai Krai Oncology Centre

Barnaul, 656043, Russian Federation

A. F.I Lazarev

Altai Branch of the N.N. Blokhin Russian Cancer Research Center

Barnaul, 656049, Russian Federation

References

  1. Lee J.K., Park H.S., Kim D.W. et al. Comparative analyses of overall survival in patients with anaplastic lymphoma kinase-positive and matched wild-type advanced nonsmall cell lung cancer. Cancer. 2012; 118: 3579-86.
  2. Soda M., Choi Y.L., Enomoto M. et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007; 448: 561-6.
  3. Al-Saad S., Al-Shibli K., Donnem T., Andersen S., Bremnes R.M., Busund L.T. Clinical significance of epidermal growth factor receptors in non-small cell lung cancer and a prognostic role for HER2 gene copy number in female patients. J. Thorac. Oncol. 2010; 5: 1536-43.
  4. Kwak E.L., Bang Y.J., Camidge D.R. et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N. Engl. J. Med. 2010; 363: 1693-703.
  5. Mino-Kenudson M., Chirieac L.R., Law K. et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin. Cancer Res. 2010; 16: 1561-71.
  6. Demidova I., Grinevich V., Avdalian A. et al. Detection of ALK rearrangements in 4002 Russian patients: The utilityof different diagnostic approaches. Lung Cancer. 2017; 103: 17-23.
  7. Warth A., Penzel R., Lindenmaier H., Brandt R., Stenzinger A., Herpel E. et al. EGFR, KRAS, BRAF and ALK gene alterations in lung adenocarcinomas: patient outcome, interplay with morphology and immunophenotype. Eur. Respir. J. 2014; 43: 872-3.
  8. Lee J.O., Kim T.M., Lee S.H. et al. Anaplastic lymphoma kinase translocation: a predictive biomarker of pemetrexed in patients with non-small cell lung cancer. J. Thorac. Oncol. 2011; 6: 1474-80.
  9. Nakamura H., Saji H., Ogata A., Hosaka M., Hagiwara M., Kawasaki N. et al. Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non-small cell lung cancer. Int. J. Cancer. 2003; 103: 61-6.

Copyright (c) 2017 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies